The effect of cinnora supplement therapy in patients with severe form of COVID-19

Phase 3

Completed

• Conditions: COVID-19 disease.; Coronavirus infection, unspecified; B34.2

• Registration Number: IRCT20180209038673N6
• Lead Sponsor: Kashan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2 May 2022

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 80

Inclusion Criteria

Patients over 18 years
Patients with definitive diagnosis of COVID-19

Exclusion Criteria

Patients who treated with tumour necrosis factor a inhibitors due to previous inflammatory diseases.
Positive purified protein derivative skin test.
Active bacterial infection.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Improvement of clinical symptoms (arterial oxygen). Timepoint: Daily evaluation of clinical signs for up to two weeks. Method of measurement: Pulse oximeter.

Secondary Outcome Measures

Name	Time	Method
C-reactive protein (CRP). Timepoint: Daily evaluation of clinical signs for up to two weeks. Method of measurement: CRP kit.